Related references
Note: Only part of the references are listed.Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children
Samantha M. Olson et al.
CLINICAL INFECTIOUS DISEASES (2022)
Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study
Anita Uka et al.
EUROPEAN JOURNAL OF PEDIATRICS (2022)
Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Old-New Vaccine Surveillance Network 2016-2017 and 2017-2018
Sara S. Kim et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Covid-19 Vaccine Effectiveness in New York State
Eli S. Rosenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
E. B. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Katherine E. Fleming-Dutra et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
A. M. Price et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022
Kristie E.N. Clarke et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
Ashley L. Fowlkes et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
Nicole P. Hachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
Sharon H. X. Tan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Ruth Link-Gelles et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years
Sara Y. Tartof et al.
JAMA NETWORK OPEN (2022)
Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020
Mark W. Tenforde et al.
CLINICAL INFECTIOUS DISEASES (2021)
Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis
Mejbah Uddin Bhuiyan et al.
VACCINE (2021)
The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020
Kathleen Dooling et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B/Victoria Viruses, 2019-2020
Angela P. Campbell et al.
CLINICAL INFECTIOUS DISEASES (2021)
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Kate R. Woodworth et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021
Megan Wallace et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19
Leigh Ellyn Preston et al.
JAMA NETWORK OPEN (2021)
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W. Frenck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
M. G. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Hospitalization of Adolescents Aged 12-17 Years with Laboratory-Confirmed COVID-19-COVID-NET, 14 States, March 1, 2020-April 24, 2021
Fiona P. Havers et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
New WHO guidelines on the management of pregnancy and breastfeeding in the context of Ebola
Anna E. Thorson et al.
LANCET INFECTIOUS DISEASES (2020)
Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19-COVID-NET, 14 States, March 1-July 25, 2020
Lindsay Kim et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Multisystem Inflammatory Syndrome in US Children and Adolescents
Leora R. Feldstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Predictors of laboratory-positive COVID-19 in children and teenagers
E. Murillo-Zamora et al.
PUBLIC HEALTH (2020)
Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance
Tri-Long Nguyen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Propensity score estimation with boosted regression for evaluating causal effects in observational studies
DF McCaffrey et al.
PSYCHOLOGICAL METHODS (2004)